2423517
Project Grant
Overview
Grant Description
SBIR Phase I: Enhancing pathology efficiency with on-chip optical coherence tomography (OCT) imaging technology.
The broader impact/commercial impacts of this Small Business Innovation Research (SBIR) Phase I project are to revolutionize pathology diagnostics through the development of an advanced imaging technology.
This project aims to introduce a silicon chip based system that will provide fast, accurate, cellular-level resolution imaging.
By improving diagnostic accuracy and reducing diagnosis times, this technology will enhance patient care, reduce the workload in pathology labs, and lower diagnostic costs.
The project supports the NSF's mission to promote scientific progress and improve national health, prosperity, and welfare by providing a technological solution with substantial commercial and societal impact.
The innovation will enhance scientific and technological understanding, address a significant market opportunity, and provide a durable competitive advantage.
The proposed business model targets pathology laboratories as the initial market segment, with projected substantial annual revenues by the third year of production.
This Small Business Innovation Research (SBIR) Phase I project focuses on developing a silicon photonic optical coherence tomography (OCT) imager for pathology diagnostics.
The primary objective is to create a high-performance, portable, and cost-effective imaging solution by integrating all optical components onto a single silicon chip.
The research will address key technical challenges, such as achieving high resolution and speed while maintaining a compact size.
The project involves designing, prototyping, and testing the OCT imager to ensure its effectiveness in accurately identifying diagnostic tissues.
The anticipated technical results include demonstrating the imager's capability to provide real-time, 3D cellular-level visualization of tissues, thereby significantly improving the pathology grossing process.
This technology is expected to set a new standard in pathology diagnostics and enable broader applications in medical imaging.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
The broader impact/commercial impacts of this Small Business Innovation Research (SBIR) Phase I project are to revolutionize pathology diagnostics through the development of an advanced imaging technology.
This project aims to introduce a silicon chip based system that will provide fast, accurate, cellular-level resolution imaging.
By improving diagnostic accuracy and reducing diagnosis times, this technology will enhance patient care, reduce the workload in pathology labs, and lower diagnostic costs.
The project supports the NSF's mission to promote scientific progress and improve national health, prosperity, and welfare by providing a technological solution with substantial commercial and societal impact.
The innovation will enhance scientific and technological understanding, address a significant market opportunity, and provide a durable competitive advantage.
The proposed business model targets pathology laboratories as the initial market segment, with projected substantial annual revenues by the third year of production.
This Small Business Innovation Research (SBIR) Phase I project focuses on developing a silicon photonic optical coherence tomography (OCT) imager for pathology diagnostics.
The primary objective is to create a high-performance, portable, and cost-effective imaging solution by integrating all optical components onto a single silicon chip.
The research will address key technical challenges, such as achieving high resolution and speed while maintaining a compact size.
The project involves designing, prototyping, and testing the OCT imager to ensure its effectiveness in accurately identifying diagnostic tissues.
The anticipated technical results include demonstrating the imager's capability to provide real-time, 3D cellular-level visualization of tissues, thereby significantly improving the pathology grossing process.
This technology is expected to set a new standard in pathology diagnostics and enable broader applications in medical imaging.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Lexington,
Massachusetts
02420-1934
United States
Geographic Scope
Single Zip Code
Lightfinder was awarded
Project Grant 2423517
worth $275,000
from National Science Foundation in August 2024 with work to be completed primarily in Lexington Massachusetts United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Enhancing Pathology Efficiency with On-Chip Optical Coherence Tomography (OCT) Imaging Technology
Abstract
The broader impact/commercial impacts of this Small Business Innovation Research (SBIR) Phase I project are to revolutionize pathology diagnostics through the development of an advanced imaging technology. This project aims to introduce a silicon chip based system that will provide fast, accurate, cellular-level resolution imaging. By improving diagnostic accuracy and reducing diagnosis times, this technology will enhance patient care, reduce the workload in pathology labs, and lower diagnostic costs. The project supports the NSF's mission to promote scientific progress and improve national health, prosperity, and welfare by providing a technological solution with substantial commercial and societal impact. The innovation will enhance scientific and technological understanding, address a significant market opportunity, and provide a durable competitive advantage. The proposed business model targets pathology laboratories as the initial market segment, with projected substantial annual revenues by the third year of production.
This Small Business Innovation Research (SBIR) Phase I project focuses on developing a silicon photonic optical coherence tomography (OCT) imager for pathology diagnostics. The primary objective is to create a high-performance, portable, and cost-effective imaging solution by integrating all optical components onto a single silicon chip. The research will address key technical challenges, such as achieving high resolution and speed while maintaining a compact size. The project involves designing, prototyping, and testing the OCT imager to ensure its effectiveness in accurately identifying diagnostic tissues. The anticipated technical results include demonstrating the imager's capability to provide real-time, 3D cellular-level visualization of tissues, thereby significantly improving the pathology grossing process. This technology is expected to set a new standard in pathology diagnostics and enable broader applications in medical imaging.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
PH
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 8/13/24
Period of Performance
8/1/24
Start Date
7/31/25
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2423517
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Other
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
L37BXCHXLJZ5
Awardee CAGE
None
Performance District
MA-05
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Modified: 8/13/24